Glad to see the pps move up but this is not the "Agreement" we have been waiting for. This seems to be nothing more than a sale of services where BDD is in the business of licensing its product technology and IPIX is the buyer. Like Dud said, similar to the sachet agreement with CoreRX (http://www.ipharminc.com/press-release/2018/7/17/innovation-pharmaceuticals-signs-drug-product-manufacturing-contract-with-corerx-to-formulate-and-package-brilacidin-for-oral-mucositis-in-sachet-form.) No details on pricing or cost of the "agreement." No idea how IPIX is "paying" for this technology. Seriously doubt they have enough cash left to pay for it outright. More shares? Who knows. Trying to be positive, one would think they would not be obtaining this technology just to have it sit around but then what have they done with the prior agreement for the production of those sachets? Apparently nothing to date.
Market Data 
Markets 
AI
